Display options
Cite
Baena A, De Vuyst H, Mesher D, et al. Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2261-2268doi: 10.1158/1055-9965.EPI-20-0422.
Baena, A., De Vuyst, H., Mesher, D., Kasubi, M., Yuma, S., Mwaiselage, J., Zouiouich, S., Mlay, P., Kahesa, C., Landoulsi, S., de la Luz Hernandez, M., Lucas, E., Herrero, R., Almonte, M., & Broutet, N. (2020). Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(11), 2261-2268. https://doi.org/10.1158/1055-9965.EPI-20-0422
Baena, Armando, et al. "Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,11 (2020): 2261-2268. doi: https://doi.org/10.1158/1055-9965.EPI-20-0422
Baena A, De Vuyst H, Mesher D, Kasubi M, Yuma S, Mwaiselage J, Zouiouich S, Mlay P, Kahesa C, Landoulsi S, de la Luz Hernandez M, Lucas E, Herrero R, Almonte M, Broutet N. Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2261-2268. doi: 10.1158/1055-9965.EPI-20-0422. Epub 2020 Aug 20. PMID: 32856600.
Copy Download .nbib Format: NLM
Share it on

Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2261-2268. doi: 10.1158/1055-9965.EPI-20-0422. Epub 2020 Aug 20.

Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Armando Baena, Hugo De Vuyst, David Mesher, Mabula Kasubi, Safina Yuma, Julius Mwaiselage, Semi Zouiouich, Pendo Mlay, Crispin Kahesa, Sihem Landoulsi, Maria de la Luz Hernandez, Eric Lucas, Rolando Herrero, Maribel Almonte, Nathalie Broutet

Affiliations

  1. Prevention and Implementation Group, Early Detection and Prevention Section, International Agency for Research on Cancer (IARC), Lyon, France.
  2. Prevention and Implementation Group, Early Detection and Prevention Section, International Agency for Research on Cancer (IARC), Lyon, France. [email protected].
  3. Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service, Public Health England, London, United Kingdom.
  4. Department of Microbiology/Immunology, Muhimbili National Hospital, Dar es Salaam, Tanzania.
  5. Reproductive and Child Health Section, Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania.
  6. Cancer Prevention Services, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
  7. Nutritional Epidemiology Group, Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC), Lyon, France.
  8. Department of Gynecology and Obstetrics, Kilimanjaro Christian Medical Centre, Kilimanjaro, Tanzania.
  9. UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland.
  10. Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer (IARC), Lyon, France.
  11. Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

PMID: 32856600 DOI: 10.1158/1055-9965.EPI-20-0422

Abstract

BACKGROUND: To inform policy makers in Tanzania if and how best to implement rapid HPV testing, we assessed the interobserver reproducibility of

METHODS: Women aged 30 to 50 years were screened by

RESULTS: Samples from 1,134 women were locally tested and retested at ReH and/or NRL. Test results from Dar es Salaam ReH and Kilimanjaro PHC showed clear quality problems including suspicion of contamination during testing or aliquoting. After excluding these samples, 18.8% of 743 women were HPV positive at clinic level. The resulting

CONCLUSIONS: Rapid HPV testing was highly reproducible between lower and higher levels of the healthcare system in Tanzania; however, performance seems to be operator dependent.

IMPACT: The

©2020 American Association for Cancer Research.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
  2. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180–90. - PubMed
  3. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–99. - PubMed
  4. Xue P, Gao LL, Yin J, Han LL, Zhao J, Li L, et al. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: detecting CIN2+ in low-resource settings. J Med Virol. 2019;91:1342–50. - PubMed
  5. Labani S, Asthana S, Sodhani P, Gupta S, Bhambhani S, Pooja B, et al. CareHPV cervical cancer screening demonstration in a rural population of north India. Eur J Obstet Gynecol Reprod Biol. 2014;176:75–9. - PubMed
  6. Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res. 2013;6:938–48. - PubMed
  7. Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador JJ, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer. 2014;24:576–85. - PubMed
  8. Tuerxun G, Yukesaier A, Lu L, Aierken K, Mijiti P, Jiang Y, et al. Evaluation of careHPV, cervista human papillomavirus, and hybrid capture 2 methods in diagnosing cervical intraepithelial neoplasia grade 2+ in Xinjiang Uyghur women. Oncologist. 2016;21:825–31. - PubMed
  9. Kelly H, Mayaud P, Segondy M, Pant Pai N, Peeling RW. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening. Sex Transm Infect. 2017;93:S36–S45. - PubMed
  10. Altman DG. Practical statistics for medical research. 1991. - PubMed
  11. R: a language and environment for statistical computing. 2020. - PubMed
  12. Dartell M, Rasch V, Kahesa C, Mwaiselage J, Ngoma T, Junge J, et al. Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study. Sex Transm Dis. 2012;39:201–8. - PubMed
  13. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer. 2000;85:206–10. - PubMed
  14. Kahesa C, Kjaer SK, Ngoma T, Mwaiselage J, Dartell M, Iftner T, et al. Risk factors for VIA positivity and determinants of screening attendances in Dar es Salaam, Tanzania. BMC Public Health. 2012;12:1055. - PubMed
  15. De Vuyst H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S, et al. The prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes Control. 2010;21:2309–13. - PubMed
  16. Beylerian EN, Slavkovsky RC, Holme FM, Jeronimo JA. Statistical modeling for quality assurance of human papillomavirus DNA batch testing. J Low Genit Tract Dis. 2018;22:219–24. - PubMed
  17. Obiri-Yeboah D, Adu-Sarkodie Y, Djigma F, Akakpo K, Aniakwa-Bonsu E, Amoako-Sakyi D, et al. Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana. Gynecol Oncol Res Pract. 2017;4:5. - PubMed
  18. Lin CQ, Chen F, Liu B, Zhang YZ, Cui XL, Li AM, et al. A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China. J Virol Methods. 2014;202:73–8. - PubMed
  19. Ying H, Jing F, Fanghui Z, Youlin Q, Yali H. High-risk HPV nucleic acid detection kit-the careHPV test-a new detection method for screening. Sci Rep. 2014;4:4704. - PubMed
  20. WHO prequalification of in vitro diagnostics: public report. 2018 Jul. - PubMed
  21. Guidelines for organizing a quality assurance program for introduction and routine use of careHPV in low-resource settings. 2017. - PubMed
  22. Gage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, et al. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer. 2012;131:2903–9. - PubMed

Publication Types

Grant support